Biogen's Busy Pipeline: Continued Confusion On BAN2401, But Other Irons In The Fire
Company highlighted recent pipeline advances in a variety of neuroscience indications during its third-quarter earnings report.
You may also be interested in...
The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.